Search
Gallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)
Mersalyl
go.drugbank.com/drugs/DB09338ExperimentalIt is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].
Pleconaril
go.drugbank.com/drugs/DB05105InvestigationalFood and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.
Potassium Iodide
go.drugbank.com/drugs/DB06715ApprovedInvestigationalSaturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radi...
Mixtures: Prenatabs FAIrofulven
go.drugbank.com/drugs/DB05786InvestigationalFood and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
OSI-7836
go.drugbank.com/drugs/DB05837ExperimentalIt is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested.
TGAAC94
go.drugbank.com/drugs/DB06175InvestigationalIn 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.
Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigational[L39060] In June 2023, the FDA approved the use of somatrogon also for the treatment of pediatric growth hormone deficiency.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalOn January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Categories: Orexin Receptor Antagonists